ESMO 2014: Inhibition of PARP, angiogenesis and immune checkpoints for ovarian cancer management

At ESMO 2014, Prof Jonathan Ledermann (University College London, UK) provides an update on the management of ovarian cancer, including maintenance therapy with the poly ADP-ribose polymerase (PARP) inhibitor, olaparib, for BRCA-mutated ovarian cancer; anti-angiogenic agents, such as cediranib; and immunomodulatory drugs, such as immune checkpoint inhibitors.

Year of Production:
Running Time:
Color/Sound:

2015
06:17
Color/Sound

Comments are closed.